ReviewBiomarkers in cancer2015
Microparticles as Biomarkers of Blood Coagulation in Cancer.
Review in Biomarkers in cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.International journal of hematology · 2017Trial
- Venous thromboembolism in ovarian cancer: pathophysiology, risk, and management.Annals of medicine and surgery (2012) · 2025Review
- Radiotherapy-the not-so-insignificant contributor to cancer-associated venous thrombosis.Research and practice in thrombosis and haemostasis · 2025Review
- Article
- Occult cancer in patients with unprovoked venous thromboembolism: A nested case-control study.American journal of clinical pathology · 2024Article
- Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer.International journal of molecular sciences · 2023Review
- Soluble P-selectin and correlation with Prothrombin Fragment 1 + 2 in myeloid malignancies in Cipto Mangunkusumo general hospital.Thrombosis journal · 2021Article
- Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy.Pathology oncology research : POR · 2020Article
- Differential biomarker profiles between unprovoked venous thromboembolism and cancer.Annals of medicine · 2020Observational
- Predicting the risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma.Heliyon · 2020Article
- Coagulation in Brain Tumors: Biological Basis and Clinical Implications.Frontiers in neurology · 2019Review
- Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis.Cancers · 2018Review
- Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.Respiratory research · 2018Observational
- The coagulome and the oncomir: impact of cancer-associated haemostatic dysregulation on the risk of metastasis.Clinical & experimental metastasis · 2018Review
- Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy.International journal of molecular sciences · 2017Review
- Extracellular vesicles and blood diseases.International journal of hematology · 2017Review
- New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.Lung Cancer (Auckland, N.Z.) · 2017Article
- Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer.BioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is associated with hypercoagulopathy and increased risk of thrombosis. This negatively influences patient morbidity and mortality. Cancer is also frequently complicated by the development of venous thromboembolism (VTE). Tumor-derived tissue factor (TF)-bearing microparticles (MPs) are associated with VTE events in malignancy. MPs are small membrane vesicles released from many different cell types by exocytic budding of the plasma membrane in response to cellular activation or apoptosis. MPs may also be involved in clinical diseases through expression of procoagulative phospholipids. The detection of TF-expressing MPs in cancer patients may be clinically useful. In lung and breast cancer patients, MPs induce metastasis and angiogenesis and may be indicators of vascular complications. Additionally, MPs in patients with various types of cancer possess adhesion proteins and bind target cells to promoting cancer progression or metastasis. Overexpression of TF by cancer cells is closely associated with tumor progression, and shedding of TF-expressing MPs by cancer cells correlates with the genetic status of cancer. Consequently, TF-expressing MPs represent important markers to consider in the prevention of and therapy for VTE complications in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.